Marc Tessier-Lavigne, Ph.D., President of The Rockefeller University, Joins Agios Board of Directors

Former Genentech Chief Scientific Officer Deepens Board's Scientific Expertise and Therapeutic Knowledge
Cambridge, Mass.

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the appointment of Marc Tessier-Lavigne, Ph.D., to its board of directors. Dr. Tessier-Lavigne is president of The Rockefeller University and formerly served as executive vice president for research and chief scientific officer at Genentech, where he directed 1,400 people in disease research and drug discovery in cancer, immune disorders, infectious diseases and neurodegenerative diseases.

"We are so pleased to welcome Dr. Tessier-Lavigne, a world-renowned scientist and member of the National Academy of Sciences, to Agios' board of directors," said David Schenkein, M.D., chief executive officer of Agios. "His participation at the leadership level of the company underscores our commitment to cutting-edge scientific research, as well as the breadth of our scientific research capabilities and the novelty of our discovery engine. Dr. Tessier-Lavigne's deep experience in drug development will be particularly valuable as we approach the next stage in our evolution, beginning to leverage our pioneering research to create a portfolio of first-in-class anticancer drugs."

Click here to view full article.